P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL

• Nigel Russell,
• Oliver Cumming,
• Jad Othman,
• Richard Dillon,
• Nicola Potter,
• Charlotte Wilhelm-Benartzi,
• Jelena Jovanovic,
• Amanda Gilkes,
• Leona Batten,
• Joanna Canham,
• Emily Laura Hinson,
• Panagiotis Kottaridis,
• Jamie Cavenagh,
• Claire Arnold,
• Mike Dennis,
• Steven Knapper

Affiliations

Nigel Russell

1 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Oliver Cumming

2 Cardiff University, Centre for Trials Research, Cardiff, United Kingdom

Jad Othman

3 Kings College London, Department of Medical and Molecular Genetics, London, United Kingdom

Richard Dillon

3 Kings College London, Department of Medical and Molecular Genetics, London, United Kingdom

Nicola Potter

3 Kings College London, Department of Medical and Molecular Genetics, London, United Kingdom

Charlotte Wilhelm-Benartzi

2 Cardiff University, Centre for Trials Research, Cardiff, United Kingdom

Jelena Jovanovic

3 Kings College London, Department of Medical and Molecular Genetics, London, United Kingdom

Amanda Gilkes

4 Cardiff University, School of Medicine, Cardiff, United Kingdom

Leona Batten

2 Cardiff University, Centre for Trials Research, Cardiff, United Kingdom

Joanna Canham

2 Cardiff University, Centre for Trials Research, Cardiff, United Kingdom

Emily Laura Hinson

2 Cardiff University, Centre for Trials Research, Cardiff, United Kingdom

Panagiotis Kottaridis

5 University College London Hospitals NHS Foundation Trust, London, United Kingdom

Jamie Cavenagh

6 St Bartholomew’s Hospital, London, United Kingdom

Claire Arnold

7 Belfast City Hospital, Belfast, United Kingdom

Mike Dennis

8 The Christie NHS Foundation Trust, Manchester, United Kingdom

Steven Knapper

9 Cardiff University, School of Medicine, on behalf of the UK NCRI AML Working Group, Cardiff, United Kingdom